• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Nuvectis Pharma Inc.

    4/28/25 4:22:27 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVCT alert in real time by email
    DEFA14A 1 tm252541d2_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment No. _____)

      

    Filed by the Registrant x
       
    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨  Preliminary Proxy Statement
    ¨  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨  Definitive Proxy Statement
    x  Definitive Additional Materials
    ¨  Soliciting Material under Rule14a-12

     

    NUVECTIS PHARMA, INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    x  No fee required.
    ¨  Fee paid previously with preliminary materials.
    ¨  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

    GRAPHIC

    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V29561-P04828 NUVECTIS PHARMA, INC. 1 BRIDGE PLAZA, SUITE 275 FORT LEE, NJ 07024 ATTN: MICHAEL CARSON NUVECTIS PHARMA, INC. 2024 Annual Meeting Vote by June 12, 2024 11:59 PM ET You invested in NUVECTIS PHARMA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on June 13, 2024. Vote Virtually at the Meeting* June 13, 2024 10:00 AM, EDT Virtually at: www.virtualshareholdermeeting.com/NVCT2024 *Please check the meeting materials for any special requirements for meeting attendance. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 30, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V29562-P04828 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of Directors Nominees: 1a. Kenneth Hoberman For 1b. Matthew Kaplan For 2. Ratify the appointment of Kesselman & Kesselman as our independent registered public accounting firm for the year ending December 31, 2024. For NOTE: Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.

    Get the next $NVCT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVCT

    DatePrice TargetRatingAnalyst
    4/2/2025$17.00Buy
    Maxim Group
    3/17/2025$19.00Buy
    Laidlaw
    7/13/2022$21.00Buy
    Ladenburg Thalmann
    3/2/2022$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NVCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mosseri Marlio Charles bought $44,768 worth of shares (5,603 units at $7.99) (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    6/24/25 5:14:35 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mosseri Marlio Charles bought $269,532 worth of shares (33,442 units at $8.06) (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    6/20/25 9:50:29 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kaplan Matthew L. was granted 30,000 shares, increasing direct ownership by 36% to 113,760 units (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    6/12/25 4:31:16 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

    Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that senior management will participate in the upcoming H.C. Wainwright Global Investment Conference. A Nuvectis corporate presentation delivered by Ron Bentsur, Chairman and Chief Executive Officer, will be available for on-demand viewing by conference attendees starting on Friday, September 5, 2025, at 7:00 a.m. ET. The Company will also attend virtual one-on-one meetings during the

    9/4/25 7:30:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

    The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of

    8/11/25 4:30:00 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

    NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminentStrengthened cash position following a July At-The-Market (ATM) shares acquisition by a healthcare-dedicated institutional investor; June 30, 2025 proforma cash position of approximately $39 million FORT LEE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious condit

    8/5/25 7:30:56 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Nuvectis Pharma with a new price target

    Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00

    4/2/25 8:05:05 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw initiated coverage on Nuvectis Pharma with a new price target

    Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00

    3/17/25 7:40:44 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

    Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00

    7/13/22 8:35:52 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mosseri Marlio Charles bought $44,768 worth of shares (5,603 units at $7.99) (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    6/24/25 5:14:35 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mosseri Marlio Charles bought $269,532 worth of shares (33,442 units at $8.06) (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    6/20/25 9:50:29 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mosseri Marlio Charles bought $171,664 worth of shares (21,167 units at $8.11) (SEC Form 4)

    4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

    5/13/25 6:36:36 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    SEC Filings

    View All

    SEC Form 10-Q filed by Nuvectis Pharma Inc.

    10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)

    8/5/25 9:30:20 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

    8/5/25 8:39:15 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

    6/13/25 5:00:08 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Financials

    Live finance-specific insights

    View All

    Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

    The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with NSCLC whose cancers developed resistance to these treatments Nuvectis will hold a conference call tomorrow, Tuesday, August 12 at 8:30 AM ET to discuss the elements of the Phase 1b program and the overall market opportunity for NXP900 Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of

    8/11/25 4:30:00 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

    SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

    11/5/24 10:55:09 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

    SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

    2/28/24 8:37:52 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nuvectis Pharma Inc.

    SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)

    2/6/24 8:47:33 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care